Uncategorized – Page 716

N-acetylcysteine versus chlorhexidine in treatment of aphthous ulcers.

PMID: J Dermatolog Treat. 2019 Nov 21:1-5. Epub 2019 Nov 21. PMID: 31679408 Abstract Title: N-acetylcysteine versus chlorhexidine in treatment of aphthous ulcers: a preliminary clinical trial. Abstract: This study sought to assess the efficacy of N-acetyl cysteine (NAC) in the treatment of recurrent aphthous stomatitis (RAS).Fifty-eight patients, aged 28 ± 9.7 years, presented with clinically diagnosed RAS …

Continue reading “N-acetylcysteine versus chlorhexidine in treatment of aphthous ulcers.”

NAC reduces hippocampal neuronal damage following transient global ischemia.

PMID: Brain Res Bull. 2019 Nov 10. Epub 2019 Nov 10. PMID: 31722253 Abstract Title: Neuroprotective effects of N-acetylcysteine via inhibition of matrix metalloproteinase in a mouse model of transient global cerebral ischemia. Abstract: N-acetylcysteine (NAC) is known to serve many biological functions including acting as an antioxidant, and electing antiinflammatory effects. Previous reports have …

Continue reading “NAC reduces hippocampal neuronal damage following transient global ischemia.”

NAC could improve the peripheral neuropathy in cirrhotic rat through suppression of MEG3/PAR2 expression.

PMID: Neurochem Int. 2019 Nov 18:104602. Epub 2019 Nov 18. PMID: 31751619 Abstract Title: N-acetylcysteine (NAC) alleviates the peripheral neuropathy associated with liver cirrhosis via modulation of neural MEG3/PAR2/ NF-ҡB axis. Abstract: BACKGROUND AND AIM: Oxidative stress (OS) is accused in pathogenesis of many diseases, including liver cirrhosis by many mechanisms. One of them is …

Continue reading “NAC could improve the peripheral neuropathy in cirrhotic rat through suppression of MEG3/PAR2 expression.”

Artesunate may be of value as a therapeutic agent for osteoarthritis.

PMID: Int J Mol Med. 2019 Oct ;44(4):1541-1551. Epub 2019 Jul 26. PMID: 31364719 Abstract Title: Artesunate alleviates interleukin‑1β‑induced inflammatory response and apoptosis by inhibiting the NF‑κB signaling pathway in chondrocyte‑like ATDC5 cells, and delays the progression of osteoarthritis in a mouse model. Abstract: Osteoarthritis (OA) is a progressive and degenerative joint disorder that is …

Continue reading “Artesunate may be of value as a therapeutic agent for osteoarthritis.”

Artesunate alleviates imiquimod-induced psoriasis-like dermatitis.

PMID: Int Immunopharmacol. 2019 Oct ;75:105817. Epub 2019 Aug 23. PMID: 31446161 Abstract Title: Artesunate alleviates imiquimod-induced psoriasis-like dermatitis in BALB/c mice. Abstract: Artesunate (ART), a derivative of artemisinin, is a medication to treat malaria. Beyond that, the anti-inflammatory and immunoregulatory activities of ART have been identified in autoimmune diseases. However, whether ART functions in …

Continue reading “Artesunate alleviates imiquimod-induced psoriasis-like dermatitis.”

Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer.

PMID: Drug Dev Res. 2019 Aug 30. Epub 2019 Aug 30. PMID: 31471932 Abstract Title: Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer. Abstract: Anti-inflammatory drugs are well known to reduce the risk of colon cancer and prophylactic use of such agents is gaining acceptance as a cancer prevention therapy. …

Continue reading “Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer.”

Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.

PMID: Biochem Biophys Res Commun. 2019 Oct 29 ;519(1):41-45. Epub 2019 Aug 31. PMID: 31481232 Abstract Title: Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Abstract: Enhancing sensitivity of carcinoma to sorafenib (Sor) is critical to overcome the limits of high frequency resistance and moderate efficiency during chemotherapy for advanced hepatocellular carcinoma (HCC). Here, we …

Continue reading “Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.”

Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt’s Lymphoma.

PMID: Biochem Biophys Res Commun. 2019 Nov 12 ;519(3):533-539. Epub 2019 Sep 16. PMID: 31537387 Abstract Title: Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt's Lymphoma. Abstract: Currently, there is no effective treatment for Burkitt's lymphoma in patients aged above 60 years, and thus research on effective treatment options for Burkitt's lymphoma has …

Continue reading “Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt’s Lymphoma.”

This mini-review will explain the present research status of Apigenin relating to cancer treatments.

PMID: Recent Pat Anticancer Drug Discov. 2019 Oct 25. Epub 2019 Oct 25. PMID: 31746310 Abstract Title: Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks. Abstract: BACKGROUND: Cancer is a global health problem and the continuous rise in incidence and mortality due to cancer carries a …

Continue reading “This mini-review will explain the present research status of Apigenin relating to cancer treatments.”

Neuroprotection by luteolin and gallic acid against cobalt chloride-induced behavioural, morphological and neurochemical alterations in Wistar rats.

PMID: Neurotoxicology. 2019 09 ;74:252-263. Epub 2019 Jul 27. PMID: 31362009 Abstract Title: Neuroprotection by luteolin and gallic acid against cobalt chloride-induced behavioural, morphological and neurochemical alterations in Wistar rats. Abstract: Cobalt (Co) intoxication arising from occupational exposures and ion release from metal implants has been associated with neurological alterations such as cognitive decline, incoordination …

Continue reading “Neuroprotection by luteolin and gallic acid against cobalt chloride-induced behavioural, morphological and neurochemical alterations in Wistar rats.”